NCT05025423View on ClinicalTrials.gov

Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

June 21, 2022

Primary Completion Date

May 14, 2025

Study Completion Date

May 14, 2025

Conditions
Mantle Cell Lymphoma
Interventions
DRUG

Venetoclax Oral Tablet [Venclexta]

Sequential dose levels for Venetoclax dependent on patient response. Fixed doses of 375 mg/m2 rituximab. Fixed dose of Bendamustine 90 mg/m2 added for those with continued PR at Cycle 8

Trial Locations (1)

21231

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

Sponsors

Collaborators (1)

AbbVie
All Listed Sponsors
collaborator

AbbVie

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER